This is a summary of the European public assessment report (EPAR) for Pritor. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pritor.
Therapeutic Indication
### Therapeutic indication **Hypertension** Treatment of essential hypertension in adults. **Cardiovascular prevention** Reduction of cardiovascular morbidity in patients with: - manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; - type-2 diabetes mellitus with documented target-organ damage.
Therapeutic Area (MeSH)
N/AATC Code
C09CA07
ATC Item
telmisartan
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Telmisartan | N/A | 替米沙坦 |
EMA Name
Pritor
Medicine Name
Pritor
Aliases
N/ANo risk management plan link.
